AGTC Hosts Topping Off Ceremony for Gene Therapy Manufacturing Facility to Celebrate the Building’s Structural Completion
– Facility in Alachua, Florida Is Expected to be Completed in the Fourth Quarter of…
Month: May 2022
aTyr Pharma to Present at Upcoming Investor Conferences in May
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics…
CinCor Reports First Quarter Financial Results and Provides Corporate Update
Topline data for baxdrostat (CIN-107) in BrigHtn Phase 2 trial for treatment-resistant hypertension (rHTN) expected…
Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update
Prelude remains on track for clinical data readouts and next steps for the PRMT5 program,…
Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial
-Orally administered SYN-020 observed to be well tolerated across all doses in healthy volunteers- ROCKVILLE,…
INmune Bio, Inc. Presents Data Demonstrating XPro™ Promotes Remyelination in Gray Matter at 3rd European Conference on Neuroinflammation
XPro™ Promotes Remyelination in a Cuprizone Model of Multiple Sclerosis(MS) by Improving Macrophage Phagocytosis (clearing) of Myelin Debris…
NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35
DURHAM, N.C., May 10, 2022 (GLOBE NEWSWIRE) — NightHawk Biosciences (NYSE American: NHWK), a fully…
Agenus Corporate Update and First Quarter 2022 Financial Report
Botensilimab data to be presented and Phase 2 trials to launch. AGEN1571 (ILT2) clinical trials…
Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
Presented Updated Clinical Data from Monotherapy Phase 1 Arm of RTX-240 Clinical Trial in Advanced…
Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update
Cystic Fibrosis Foundation (CF Foundation) awarded up to $15.9 million for the ongoing ELX-02 clinical program Topline data from cystic fibrosis (CF) Phase 2…
Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights
Ovid anticipates filing an investigational new drug application (IND) for OV329, a potent GABA aminotransferase…
Science 37® Extends Leadership in Decentralized Clinical Trial Market with NextGen SaaS Release to Fully Orchestrate Decentralized Study Conduct
New release sets the bar as the most comprehensive platform to orchestrate decentralized study conduct—unifying…
NexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors
GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company…
Acerus Reports First Quarter 2022 Financial Results
TORONTO, May 10, 2022 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:…
Corvus Pharmaceuticals Provides Program Updates at R&D Symposium
Highlights new interim data from CPI-818 Phase 1/1b study in patients with relapsed T cell…
Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
– SNS-101 preclinical data provide encouraging validation of pH-sensitive approach to inhibiting VISTA with high…
Dante Labs receives grant by Italian government to pilot revolutionary CE-IVD, clinical whole genome sequencing-based Citizen Test for a G7 country, starting a new era in clinical genomics
NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) — Dante Labs, a global leader in genomics…
Theratechnologies Initiates Basket Portion of TH1902 First-in-Human Study in Advanced Resistant Malignancies
Phase 1b dose established at 300 mg/m2 or 1.5 times the therapeutic dose of docetaxel…
Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business Highlights
– Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trial…
PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights
Oral presentation at 2022 ASCO annual meeting to highlight initial data from ongoing Phase 1/2…